Telix says IPAX-1 Phase I study published in Neuro-Oncology Advances

Telix Pharmaceuticals Limited announced that the company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation therapy in recurrent glioblastoma, the most common and aggressive form of primary brain cancer. TLX101 is a systemically administered targeted radiation therapy that targets L-type amino acid transporter 1, which is typically over-expressed in GBM. In the first peer-reviewed publication of the IPAX-1 study, Professor Josef Pichler and colleagues report that single or fractionated doses of TLX101 plus EBRT were associated with acceptable tolerability and specific tumor-targeting in patients with recurrent GBM. Authors explain that the study delivered encouraging preliminary efficacy data, demonstrating a median overall survival of 13 months from the initiation of treatment, or 23 months from initial diagnosis. Given that GBM has a median survival from initial diagnosis of 12-15 months, authors conclude that findings from the IPAX-1 study “support further investigation into the use of TLX101 plus EBRT, including its potential as a first line treatment”.